In Brief
This article was originally published in The Tan Sheet
Executive Summary
FDA proposes amending ANDA-blocking petition reg; Sara Lee snaps up Tea Forté; testing by FDA, CDC find no bacteria in Enfamil formula powder; USP offers draft probiotics standards; more news In Brief.
You may also be interested in...
FDA Reprimands Snake Venom Seller For Pain Claims Amid Opioid Crisis
Nutra Pharma’s Nyloxin claims to relieve cancer pain and potentially help treat opioid addiction, among others, mark its products as unapproved new drugs, FDA asserts in a warning letter that reflects its homeopathic enforcement approach proposed in late 2017. “Health fraud scams like these are inexcusable,” says FDA Commissioner Scott Gottlieb.
Gluten-Drug Rule Petitioner Claims Time Has Expired For FDA Decision
A lawsuit seeks to declare FDA’s failure to act on a 2008 citizen petition requesting a ban of wheat gluten in OTCs and Rx drugs in violation of the Administrative Procedure Act. The complaint alleges the agency’s delay is unreasonable and asks the court to order FDA to make a decision within 30 days.
Gluten-Drug Rule Petitioner Claims Time Has Expired For FDA Decision
A lawsuit seeks to declare FDA’s failure to act on a 2008 citizen petition requesting a ban of wheat gluten in OTCs and Rx drugs in violation of the Administrative Procedure Act. The complaint alleges the agency’s delay is unreasonable and asks the court to order FDA to make a decision within 30 days.